A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
← catalyst calendarSponsored by Design Therapeutics, Inc. (industry) · DSGN — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
36estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Feb 2025 | estimated | When the study began enrolling |
| Primary completion | Sep 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Friedreich Ataxia
Interventions
- Drug: DT-216P2
- Drug: Saline
Primary outcome
what the primary-completion date above is the date OFFrequency of treatment emergent adverse events (TEAEs)
measured From first dose to end of study, Day 30 post first dose administration.
Permalink · DSGN's whole pipeline · Catalyst calendar · Every registered study · What changed